Oppenheimer Keeps Their Buy Rating on Ascendis Pharma (ASND)
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Ascendis Pharma, with a price target of $262.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gershell covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Capricor Therapeutics, and CalciMedica. According to TipRanks, Gershell has an average return of 4.6% and a 40.81% success rate on recommended stocks.
In addition to Oppenheimer, Ascendis Pharma also received a Buy from Morgan Stanley’s Maxwell Skor in a report issued today. However, on January 28, TipRanks – Google reiterated a Hold rating on Ascendis Pharma (NASDAQ: ASND).
Read More on ASND:
Disclaimer & DisclosureReport an Issue
- Ascendis Pharma price target raised to $256 from $250 at Morgan Stanley
- Ascendis Pharma: Strong Yorvipath Momentum, Pipeline Upside, and Raised DCF Assumptions Underpin Buy Rating and $260 Target
- Ascendis Pharma: Accelerating Commercial Momentum and Pipeline Execution Support Higher Target and Buy Rating
- ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside
- Ascendis Pharma Posts Strong 2025 Results as YORVIPATH Drives Growth and TransCon Pipeline Advances
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.